System Certification ISO 9001:2000
Exbio Antibodies CZ / SK eShop
by categories | a-z list | Application type: Flow Cytometry | Immunohistochemistry | Functional Studies

Mouse Monoclonal to p53

BP53-12 (IgG2a)

Technical Information Request    Inquiry for Bulk Prices

Product No. Form Quantity Stock Price Datasheet Shop
  11-114-C025 purified 0.025 mg yes choose region PDF datasheetHTML datasheet buy
  11-114-C100 purified 0.1 mg yes choose region PDF datasheetHTML datasheet buy
  1F-114-C025 FITC 0.025 mg yes choose region PDF datasheetHTML datasheet buy
  1F-114-C100 FITC 0.1 mg yes choose region PDF datasheetHTML datasheet buy
- In stock! Ready for immediate despatch - Manufacture on order


The tumour suppressor protein p53 is a key element of intracellular anticancer protection. It mediates cell cycle arrest or apoptosis in response to DNA damage or to starvation for pyrimidine nukleotides. It is up-regulated in response to these stress signals and stimulated to activate transcription of specific genes, resulting in expression of p21waf1 and other proteins involved in G1 or G2/M arrest, or proteins that trigger apoptosis, such as Bcl-2. The structure of p53 comprises N-terminal transactivation domain, central DNA-binding domain, oligomerisation domain, and C-terminal regulatory domain. There are various phosphorylation sites on p53, of which the phosphorylation at Ser15 is important for p53 activation and stabilization.


The antibody BP53-12 recognizes defined epitope (aa 16-25) on human p53, a 50 kDa tumour suppressor found in increased amounts in a wide variety of transformed cells; it is frequently mutated or inactivated in many types of cancer.

Regulatory Status


Bacterially expressed full-length wild-type p53

Species Reactivity:

  • Human
  • Non-Human Primates

Negative Species:


  • Immunoprecipitation
  • Western Blotting
    Recommended dilution: 1-2 μg/ml, overnight in 4░C
    Positive control: RAMOS human lymphoma cell line
    Sample preparation: Resuspend approx. 50 mil. cells in 1 ml cold Lysis buffer (1% laurylmaltoside in 20 mM Tris/Cl, 100 mM NaCl pH 8.2, 50 mM NaF including Protease inhibitor Cocktail). Incubate 60 min on ice. Centrifuge to remove cell debris. Mix lysate with non-reducing SDS-PAGE sample buffer.
    Application note: Non-reducing conditions. SDS-PAGE (12% separating gel).
  • Immunohistochemistry (paraffin sections)
  • Immunocytochemistry
Usage note:
Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.

General references

  • *Agarwal ML, Agarwal A, Taylor WR, Stark GR: p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8493-7. [Abstract] [Full Text]
  • *Agarwal ML, Agarwal A, Taylor WR, Chernova O, Sharma Y, Stark GR: A p53-dependent S-phase checkpoint helps to protect cells from DNA damage in response to starvation for pyrimidine nucleotides. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14775-80. [Abstract] [Full Text]
  • *Taylor WR, DePrimo SE, Agarwal A, Agarwal ML, Sch÷nthal AH, Katula KS, Stark GR: Mechanisms of G2 arrest in response to overexpression of p53. Mol Biol Cell. 1999 Nov;10(11):3607-22. [Abstract] [Full Text]
  • *Taylor WR, Agarwal ML, Agarwal A, Stacey DW, Stark GR: p53 inhibits entry into mitosis when DNA synthesis is blocked. Oncogene. 1999 Jan 14;18(2):283-95. [Abstract] [Full Text]
  • *Tanigawa S, Fujii M, Hou DX: Stabilization of p53 is involved in quercetin-induced cell cycle arrest and apoptosis in HepG2 cells. Biosci Biotechnol Biochem. 2008 Mar;72(3):797-804. [Abstract] [Full Text]
  • Product Specific References

  • *Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, Kovarik J, Midgley CA, Gannon JV, Lane DP: Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene. 1991 Sep;6(9):1699-703. [Abstract]
  • *Bartkova J, Bartek J, Lukas J, Vojtesek B, Staskova Z, Rejthar A, Kovarik J, Midgley CA, Lane DP: p53 protein alterations in human testicular cancer including pre-invasive intratubular germ-cell neoplasia. Int J Cancer. 1991 Sep 9;49(2):196-202. [Abstract]
  • *Dolezalova H, Vojtesek B, Kovarik J: Epitope analysis of the human p53 tumour suppressor protein. Folia Biol (Praha). 1997;43(1):49-51. [Abstract]
  • For research use only. Not for drug, diagnostic or other use.

    Related Products

  • Mouse IgG2a Isotype Control
  • Example Data

    Confocal microscopy of human HeLa cells, stained with p53-FITC monoclonal antibody BP53-12
    Fig. 1.

    Fig. 1. Confocal microscopy of human HeLa cells using anti-p53 (BP53-12; FITC). The expression of p53 protein was enhanced by intercalating reagent. Cells were fixed and permeabilized before incubation with the p53-FITC MAb.

    Photo provided by Dr. Hodny, Inst. of Experimental Medicine, Prague, Czech Republic

    Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO┤s term and conditions which are available at
    © 2003 EXBIO. All rights reserved.
    terms and conditions | privacy policy